211
Participants
Start Date
September 24, 2019
Primary Completion Date
June 30, 2024
Study Completion Date
June 30, 2024
Ixazomib
the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group
Lenalidomide
the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
PekingUMCH, Beijing
Peking University Third Hospital
OTHER
Beijing Jishuitan Hospital
OTHER
Beijing Chao Yang Hospital
OTHER
Xuanwu Hospital, Beijing
OTHER
Peking University First Hospital
OTHER
Jilin Provincial Tumor Hospital
OTHER
Second Hospital of Shanxi Medical University
OTHER
The First Affiliated Hospital of Shanxi Medical University
OTHER
Tianjin Medical University General Hospital
OTHER
The First Affiliated Hospital of Anhui Medical University
OTHER
Shanxi Bethune Hospital
OTHER
Beijing Hospital
OTHER_GOV
Peking Union Medical College Hospital
OTHER